SGLT2 inhibitor

Phase 3Small molecule

Eli Lilly

SGLT2 inhibitor is one of 387 small molecule programs targeting Ascites. It is currently in Phase 3.

Indications

Total Trials

Active Trials

386

Competitors

Pipeline

Status by Indication[3][1]

Indication

AscitesActive, not recruiting

Post-Operative Atrial FibrillationActive, not recruiting

Metabolic DiseaseActive, not recruiting

Myocardial InfarctionActive, not recruiting

Oxidative StressActive, not recruiting

AnemiaActive, not recruiting

Atrial FibrillationActive, not recruiting

Type 1 DiabetesActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

OsteoarthritisActive, not recruiting

AscitesPreclinical

Active, not recruiting

Post-Operative Atrial FibrillationPreclinical

Active, not recruiting

Metabolic DiseasePreclinical

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Oxidative StressPreclinical

Active, not recruiting

AnemiaPreclinical

Active, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Type 1 DiabetesPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

SGLT2 inhibitor

Eli Lilly

Phase 3

3 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Active, not recruiting

Chronic Kidney Disease

NCT07063316

Post-ApprovalRecruiting

Tetralogy of Fallot

NCT06668389

Recruiting

Ascites

NCT05999773

Recruiting

Acute Myocardial Infarction

NCT05770687

Q1 2027

Not yet recruiting

Osteoarthritis

NCT07360457

Q3 2027

Not yet recruiting

Type 2 Diabetes Mellitus

NCT07723820

Clinical

Trials by Indication[1]

Type 2 Diabetes10 trials

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT03214380·933 enrolled

Approaches To Therapy Escalation In T2D

Withdrawn·LLMC Diabetes & Endocrinology Ltd.·Phase 4·NCT03813316

Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Unknown status·UUniversity of Milan··NCT05477017·800 enrolled

Show 7 more trials

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Unknown status·MMackay Memorial Hospital·Phase 4·NCT03458715·120 enrolled

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Completed· Sanofi logo

Sanofi·Phase 3·NCT03798054·878 enrolled

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

Completed·UUniversity of Texas Southwestern Medical Center··NCT05033054·33 enrolled

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Recruiting·—·Phase 4·NCT05390892·6,000 enrolled

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Completed·SSamsung Medical Center··NCT07332156·21,692 enrolled

Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes

Recruiting· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical··NCT06838286·10,000 enrolled

Efficacy and Safety of Incorporating Sodium-glucose Cotransporter-2 Inhibitors to Regimens of Patients With Type 2 Diabetes

Completed·AAssiut University·Approved·NCT06268977·482 enrolled

SGLT2 Inhibitors4 trials

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Active, not recruiting·UUniversity of Patras··NCT05408936·80 enrolled

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors

Unknown status·UUniversity of Turin, Italy·N/A·NCT03917758·30 enrolled

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Recruiting·NNational Taiwan University Hospital·Phase 3·NCT06142474·450 enrolled

Show 1 more trial

Effect of SGLT2 Inhibitors on Anemic CKD Patients

Not yet recruiting·SSohag University··NCT07334145·60 enrolled

Type 2 Diabetes Mellitus4 trials

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02597049·424 enrolled

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Unknown status·SSohag University·Phase 3·NCT06117137·150 enrolled

Glycemic Velocity as a Modifiable Determinant of Early Retinal Microvascular and Choroidal Change During Initiation of GLP-1 Receptor Agonist Versus SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Multimodal Retinal Imaging Cohort Study (the GLIDE Study)

Not yet recruiting·TThammasart University Hospital··NCT07723820·126 enrolled

Show 1 more trial

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Therapeutic Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of JP-2266 in Patients With Type 2 Diabetes Mellitus

Completed· Jeil Pharmaceutical Co., Ltd. logo

Jeil Pharmaceutical Co., Ltd.·Phase 2·NCT06144788·161 enrolled

Heart Failure3 trials

Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion

Unknown status·SSequana Medical N.V.·N/A·NCT04882358·24 enrolled

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Active, not recruiting·—··NCT06901609·200 enrolled

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting·SSamsung Medical Center·Phase 4·NCT06350487·154 enrolled

SGLT-2 Inhibitor2 trials

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Unknown status·—··NCT05333159·1,424 enrolled

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Completed·UUniversity of Padova··NCT04184947·10,000 enrolled

39 more indications

Chronic Kidney Disease2 trials

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Completed·WWeill Medical College of Cornell University··NCT03921242·4,888 enrolled

Effect of SGLT2 Inhibitors on Renal Anemia and Its Management in Patients With CKD in Japan

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT07063316·15,000 enrolled

Acute Myocardial Infarction2 trials

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Recruiting·KKiyuk Chang··NCT05770687·1,000 enrolled

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention

Recruiting·SSamsung Medical Center·Phase 4·NCT04899479·200 enrolled

Tetralogy of Fallot1 trial

Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial

Recruiting·TThe University of Hong Kong·Phase 4·NCT06668389·106 enrolled

Acute Kidney Injury1 trial

SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot

Terminated·UUniversity of Minnesota·Phase 1·NCT06124924·1 enrolled

Ketosis1 trial

Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers

Active, not recruiting·—·Phase 1·NCT05662865·9 enrolled

Kidney Transplant1 trial

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

Completed·WWest China Hospital·N/A·NCT05013112·105 enrolled

Platelet Function1 trial

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.

Completed·TThe University of The West Indies·Phase 2/3·NCT04342819·25 enrolled

Cardiovascular Disease1 trial

Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes

Unknown status·YYonsei University·Phase 4·NCT05975528·92 enrolled

Ascites1 trial

SGLT-2 Inhibitors in the Treatment of Ascites

Recruiting·UUniversity of Palermo··NCT05999773·40 enrolled

ALS1 trial

Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT05934071·160 enrolled

COVID-191 trial

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Completed·MMatthew Neal MD·Phase 4·NCT04505774·3,591 enrolled

Atrial Fibrillation1 trial

The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus

Enrolling by invitation·EEwha Womans University Mokdong Hospital··NCT05029115·716 enrolled

Alport syndrome1 trial

Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

Recruiting·UUniversity Hospital Goettingen··NCT02378805·800 enrolled

Perioperative Period1 trial

SGLT2 Inhibitors and Perioperative Period

Not yet recruiting·—··NCT06326528·100 enrolled

Diabetes1 trial

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

Completed·UUniversity of California, San Francisco·N/A·NCT02846233·22 enrolled

Proteinuria1 trial

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Unknown status·NNahla H Tohami·Phase 4·NCT03573102·60 enrolled

Myocardial Infarction1 trial

Role of SGLT2I in Patients With Myocardial Infarction

Unknown status·DDongying Zhang··NCT06245980·1,200 enrolled

Oxidative Stress1 trial

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

Recruiting·KKafrelsheikh University··NCT06585761·60 enrolled

TIA1 trial

Initiation of ARNi and SGLT2i in Patients With HFrEF

Completed·UUniversidade do Porto·Phase 4·NCT05989503·62 enrolled

Metabolic Disease1 trial

Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes

Unknown status·YYonsei University··NCT03204799·150 enrolled

Renal Transplantation1 trial

SGLT2i in Diabetic Patients with Renal Transplantation

Active, not recruiting·—·Phase 1/2·NCT06731231·72 enrolled

Type 2 Diabetic Patients1 trial

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 4·NCT03631134·100 enrolled

Aortic Valve Stenosis1 trial

Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention

Unknown status·UUniversity of Aarhus·Phase 2/3·NCT05241431·106 enrolled

Osteoarthritis1 trial

GLP1 Analogues and the Risk of Osteoarthritis

Not yet recruiting·—··NCT07360457·390 enrolled

ART1 trial

iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

Completed· Sanofi logo

Sanofi·Phase 3·NCT05413369·582 enrolled

Kidney1 trial

Mechanism of SGLT2 Inhibition in the Kidney

Recruiting·UUniversity of Michigan·Phase 4·NCT06291155·20 enrolled

Tics1 trial

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

Completed· Jeil Pharmaceutical Co., Ltd. logo

Jeil Pharmaceutical Co., Ltd.·Phase 1·NCT06165965·48 enrolled

Post-Operative Atrial Fibrillation1 trial

Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery

Unknown status·HHamad Medical Corporation··NCT06251453·3,280 enrolled

GLP-11 trial

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Recruiting·—··NCT07309094·250 enrolled

CAR1 trial

Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency

Completed·WWashington University School of Medicine·Phase 4·NCT05541484·21 enrolled

Heart1 trial

Gliflozins on HF in Regurgitant Rheumatic Heart

Unknown status·—··NCT06097585·150 enrolled

Microbiota1 trial

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

Completed·UUniversity of Tartu··NCT04151849·23 enrolled

Non-Alcoholic Steatohepatitis1 trial

SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis

Completed·UUniversity of Oxford·Phase 1·NCT02696941·20 enrolled

Type 1 Diabetes1 trial

EFFECT OF HYBRID CLOSED-LOOP SYSTEMS ON CARDIOVASCULAR MARKERS IN TYPE 1 DIABETES.

Active, not recruiting·—··NCT07241702·100 enrolled

Hyperglycemia1 trial

Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial

Unknown status·ZZealand University Hospital·Phase 2·NCT05314725·24 enrolled

Duchenne Muscular Dystrophy (DMD)1 trial

duCHennE caRdiomyopathy mItigation Sglt2 inHibitor

Recruiting·LLarry W. Markham·Phase 1·NCT07172971·10 enrolled

Cardiovascular Events1 trial

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

Active, not recruiting·BBrigham and Women's Hospital··NCT05220917·781,430 enrolled

Type 2 Diabetes Mellitus (T2DM)1 trial

Integrative Genetic, Molecular and Behavioural Determinants of Cognitive Decline in Type 2 Diabetes: SGLT2 Inhibitors as a Model for Secondary and Tertiary Prevention (SaveMinD)

Active, not recruiting·UUniversity of Primorska·Preclinical·NCT07694596·200 enrolled

Cardiovascular-kidney-metabolic Syndrome1 trial

Associations of Early Add-On GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy With Mortality and Kidney Outcomes in Adults With Obesity and Type 2 Diabetes Across Cardiovascular-Kidney-Metabolic Stages 2-3: A Target-Trial Emulation

Completed·CChung Shan Medical University··NCT07465926·451,036 enrolled

Sources

References

[1]
ClinicalTrials.gov — 64 trial records for SGLT2 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SGLT2 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SGLT2 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

SGLT2 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Trials by Indication[1]

Type 2 Diabetes10 trials

SGLT2 Inhibitors4 trials

Type 2 Diabetes Mellitus4 trials

Heart Failure3 trials

SGLT-2 Inhibitor2 trials

Chronic Kidney Disease2 trials

Acute Myocardial Infarction2 trials

Tetralogy of Fallot1 trial

Acute Kidney Injury1 trial

Ketosis1 trial

Kidney Transplant1 trial

Platelet Function1 trial

Cardiovascular Disease1 trial

Ascites1 trial

ALS1 trial

COVID-191 trial

Atrial Fibrillation1 trial

Alport syndrome1 trial

Perioperative Period1 trial

Diabetes1 trial

Proteinuria1 trial

Myocardial Infarction1 trial

Oxidative Stress1 trial

TIA1 trial

Metabolic Disease1 trial

Renal Transplantation1 trial

Type 2 Diabetic Patients1 trial

Aortic Valve Stenosis1 trial

Osteoarthritis1 trial

ART1 trial

Kidney1 trial

Tics1 trial

Post-Operative Atrial Fibrillation1 trial

GLP-11 trial

CAR1 trial

Heart1 trial

Microbiota1 trial

Non-Alcoholic Steatohepatitis1 trial

Type 1 Diabetes1 trial

Hyperglycemia1 trial

Duchenne Muscular Dystrophy (DMD)1 trial

Cardiovascular Events1 trial

Type 2 Diabetes Mellitus (T2DM)1 trial

Cardiovascular-kidney-metabolic Syndrome1 trial

References

Drug Info

Quick Facts

Related News